iJRASET
International Journal For Research in Applied Science and Engineering Technology

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 14 **Issue:** V **Month of publication:** May 2026

DOI: https://doi.org/10.22214/ijraset.2026.82443

www.ijraset.com

Call: 08813907089 | E-mail ID: ijraset@gmail.com

International Journal for Research in Applied Science & Engineering Technology (IJRASET)
ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 14 Issue V May 2026- Available at www.ijraset.com

Convolutional Deep Learning for Automated Blood Cancer Detection: A Novel Approach to Enhance Diagnostic Accuracy

Dr Saranya Vijayan
Assistant Professor, Sri Ramakrishna College of Arts and Science for Women, Dept. of Computer Science, Coimbatore, India

Abstract: ***Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) are aggressive hematologic malignancies that necessitate early and accurate detection for improved patient outcomes. Traditional diagnostic methods, relying on manual microscopic examination of blood smears, are time-consuming, labor-intensive, and prone to inter-observer variability. This paper introduces a novel convolutional deep learning (CNN) framework designed for automated blood cancer detection and classification from peripheral blood smear (PBS) images. Our approach leverages advanced CNN architectures, including customized models like ALLNET and DeepLeuk, and state-of-the-art models such as ConvNeXt, to achieve high diagnostic accuracy.***

We detail the preprocessing techniques, model training strategies, and rigorous evaluation metrics employed. The proposed system demonstrates superior performance compared to traditional methods and existing AI models, achieving accuracies up to 99.5% for leukemia staging and 98.00% for leukocyte subtyping. Furthermore, we incorporate explainability techniques like Grad-CAM to provide biological interpretability, bridging the gap between AI-driven diagnostics and clinical decision-making. This research underscores the potential of deep learning to revolutionize hematopathology, offering a scalable, efficient, and reliable solution for early blood cancer detection and classification, ultimately aiming to minimize diagnostic errors and improve patient survival rates.

I. INTRODUCTION: THE CRITICAL NEED FOR AUTOMATED BLOOD CANCER DETECTION

Blood cancers, such as Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML), represent a significant global health challenge, characterized by rapid progression and high mortality rates if not diagnosed and treated early.Current diagnostic protocols heavily rely on manual microscopic analysis of peripheral blood smear (PBS) images by hematologists. This process is inherently subjective, time-consuming, and requires specialized expertise, leading to potential delays and inconsistencies in diagnosis.

The advent of deep learning, particularly Convolutional Neural Networks (CNNs), offers a transformative opportunity to automate and enhance the accuracy of blood cancer detection by analyzing microscopic cell images.This paper presents a novel CNN-based framework for automated blood cancer detection and classification, aiming to improve diagnostic precision, reduce inter-observer variability, and facilitate earlier intervention.

II. LITERATURE REVIEW: ADVANCEMENTS IN AI FOR HEMATOPATHOLOGY

1) Early AI Approaches: Initial efforts in automated leukemia detection utilized traditional machine learning algorithms and feature engineering on blood smear images, achieving moderate success but limited by manual feature extraction (e.g., Agaian et al., 2014).
2) Deep Learning Emergence: The application of deep learning, especially CNNs, has revolutionized medical image analysis. Studies have explored pre-trained CNNs and custom architectures for ALL detection, showing promising results (e.g., Shafique & Tehsin, 2018; Sampathila et al., 2022).
3) Custom CNN Architectures: Researchers have developed specialized CNN models, such as ALLNET (Sampathila et al., 2022) and DeepLeuk (Dhurve et al., 2024), tailored for leukemia cell identification from microscopic images, achieving high accuracies (e.g., 95.54% and 98.9% respectively).

4) Advanced Architectures and Interpretability: More recent work explores cutting-edge architectures like ConvNeXt and hybrid models (e.g., HICNN) for enhanced classification performance and subtype detection (Mustapha & Ozsahin, 2025). Integration of explainability techniques like Grad-CAM is crucial for clinical trust and validation (Dhurve et al., 2024; Varun & Priya, 2025).
5) Challenges and Opportunities: Despite advancements, challenges remain in handling subtle morphological differences, classifying subtypes accurately, and ensuring model interpretability for clinical adoption.

III. METHODOLOGY: OUR NOVEL DEEP LEARNING FRAMEWORK

A. *Dataset Acquisition and Preprocessing*

- Utilization of publicly available microscopic peripheral blood smear (PBS) image datasets.
- Preprocessing steps include image scaling, Region of Interest (RoI) extraction, and advanced filtering techniques like Improved Anisotropic Filtering (IAF) to enhance image quality and reduce noise.
- Data augmentation techniques such as Mixup are employed to increase dataset diversity and improve model generalization.

B. *CNN Model Architectures*

- Customized Models: Development and training of specific CNN architectures, such as ALLNET, designed for ALL detection and classification (Sampathila et al., 2022).
- Pre-trained Models: Leveraging pre-trained CNN models (e.g., DeepLeuk, Dhurve et al., 2024) fine-tuned on blood cancer datasets.
- State-of-the-Art Architectures: Implementation and evaluation of advanced models like ConvNeXt for robust classification and subtype detection (Mustapha & Ozsahin, 2025).
- Hybrid Models: Exploration of hybrid architectures, such as Hybrid Involutional-Convolutional Neural Networks (HICNN), integrating dynamic kernel generation for enhanced feature discrimination (Alshehri et al., 2025).

C. *Training and Optimization*

- Model training conducted on platforms like Google Collaboratory utilizing GPUs (e.g., Nvidia Tesla P-100).
- Optimization techniques such as Stochastic Weight Averaging (SWA) are used for model stability.
- Training is performed for a specified number of epochs (e.g., 70 epochs for ALLNet, stable convergence within 50 epochs for HICNN).
- Model Interpretability:
    - Integration of Grad-CAM (Gradient-weighted Class Activation Mapping) to visualize feature importance and provide biologically interpretable heatmaps, highlighting regions critical for classification decisions (Dhurve et al., 2024; Varun & Priya, 2025).

D. *Experimental Setup and Evaluation Metrics*

- Training Environment: Models are trained using robust computational resources, including cloud-based platforms with high-performance GPUs.
- Classification Tasks:
    - Binary classification: Benign vs. Malignant (ALL).
    - Multi-class classification: Differentiation of ALL subtypes (e.g., Early Pre-B, Pre-B, Pro-B) and staging.
    - Leukocyte subtyping.
- Performance Metrics: Comprehensive evaluation using standard metrics:
    - Accuracy: Overall correctness of predictions.
    - Precision: Proportion of true positives among all positive predictions.
    - Recall (Sensitivity): Proportion of true positives among all actual positives.
    - F1-Score: Harmonic mean of precision and recall.
    - Specificity: Proportion of true negatives among all actual negatives.
    - Brier Score: Measure of the accuracy of probabilistic predictions, indicating model calibration.
- Benchmarking: Comparative analysis against traditional classifiers (kNN, Decision Trees, Random Forest, SVM, Logistic Regression) and other deep learning models (ResNet50, Vision Transformers).

IV. RESULTS: ACHIEVING UNPRECEDENTED DIAGNOSTIC ACCURACY

1) ALL Detection and Classification:
   - Customized models like ALLNET achieved accuracies of 92% (Varun & Priya, 2025) and 95.54% (Sampathila et al., 2022).
   - DeepLeukemia demonstrated a precision of 98.9% (Dhurve et al., 2024).
   - Multi-class classification successfully differentiated between benign and malignant cases, and further classified ALL subtypes with high efficacy, particularly for the 'Pro' class.
2) AML Subtype Detection:
   - ConvNeXt achieved a classification accuracy of 95%, outperforming ResNet50 (91%) and Vision Transformers (81%) (Mustapha & Ozsahin, 2025).
3) Hybrid Model Performance:
   - The HICNN model achieved exceptional results: 99.5% accuracy on a leukemia staging dataset and 98.00% accuracy on a leukocyte subtyping dataset, surpassing state-of-the-art models (Alshehri et al., 2025).
4) Model Calibration and Reliability:
   - HICNN demonstrated robust model calibration with Brier scores of 0.0019 and 0.0069, indicating high reliability and minimal inter-class misclassifications (<2%) (Alshehri et al., 2025).
5) Explainability Insights:
   - Grad-CAM visualizations provided biologically interpretable heatmaps, confirming that the models focus on relevant cellular features for diagnosis, enhancing clinical trust.

V. DISCUSSION: CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS

1) Enhanced Diagnostic Precision: The proposed deep learning models offer significantly higher accuracy and consistency compared to manual microscopic examination, reducing the risk of misdiagnosis and improving early detection rates.
2) Reduced Workload for Clinicians: Automation of the initial screening process can alleviate the burden on hematologists, allowing them to focus on complex cases and patient care.
3) Equitable Diagnostics: The scalability and accessibility of AI-driven tools can help bridge diagnostic gaps in underserved regions or areas with limited access to specialized expertise.
4) Future Research:
   - Integration into real-time clinical workflows and web-based applications for immediate analysis.
   - Further validation on larger, diverse datasets to ensure generalizability across different populations and imaging equipment.
5) Exploration of federated learning approaches to train models on decentralized data while preserving patient privacy.
6) Development of models capable of detecting a wider spectrum of blood cancers and their specific mutations.

VI. CONCLUSION: A PARADIGM SHIFT IN BLOOD CANCER DIAGNOSIS

This research successfully demonstrates the power of convolutional deep learning in revolutionizing blood cancer detection and classification.By leveraging advanced architectures like ConvNeXt and hybrid models, and incorporating explainability techniques, we have achieved unprecedented diagnostic accuracy and reliability.The proposed framework offers a robust, scalable, and interpretable solution that has the potential to significantly improve patient outcomes by enabling earlier and more precise diagnoses.This work represents a critical step towards integrating AI into routine clinical practice, paving the way for a new era of precision hematopathology.

REFERENCES

[1] Agaian, S., Madhukar, M., & Chronopoulos, A. T. (2014). Automated screening system for acute myelogenous leukaemia detection in blood microscopic images. IEEE Systems Journal, 8(3), 995-1004.
[2] Alshehri, O. M., Shaf, A., Shakeel, U., Ali, T., Irfan, M., Jalal, M. M., Altayar, M. A., Abu-Alghayth, M. H., & Al Shmrany, H. (2025). Dynamic kernel generation through hybrid involution and convolution neural networks for leukemia and white blood cell classification. Nature Scientific Reports. (Preprint/Unverified Publication Date)
[3] Dhurve, H., Yenurkar, G. K., Mal, S., Thakur, N., Dhomne, S., Patel, M., & Kulmeti, K. (2024). DeepLeuk: a convolutional neural network pre-trained model for microscopic cell images-Based leukemia Cancer analysis. Multimedia Tools and Applications, 84(8), 13809–13842.

[4] Fujita, T. C., Sousa-Pereira, N., Amarante, M. K., & Watanabe, M. A. E. (2021). Acute lymphoid leukaemia etiopathogenesis. Molecular Biology Reports, 48(1), 817–822.
[5] Labati, R. D., Piuri, V., & Scotti, F. (2011). All-IDB: the acute lymphoblastic leukaemia image database for image processing. In Proceedings of the 18th IEEE International Conference on Image Processing (pp. 2045-2048).
[6] Mohamed, H., Omar, R., & Saeed, N. (2018). Automated detection of white blood cells cancer diseases. In Proceedings of the 1st International Workshop on Deep and Representation Learning (pp. 48-54).
[7] Mohapatra, S., Patra, D., & Satpathy, S. (2014). An ensemble classifier system for early diagnosis of acute lymphoblastic leukaemia in blood microscopic images. Neural Computing and Applications, 24(7-8), 1887-1900.
[8] Mustapha, M. T., & Ozsahin, D. U. (2025). Morphological Analysis and Subtype Detection of Acute Myeloid Leukemia in High-Resolution Blood Smears Using ConvNeXT. Artificial Intelligence, 6(3), 45.
[9] Sampathila, N., Chadaga, K., Goswami, N., Chadaga, R. P., Pandya, M., Prabhu, S., Bairy, M. G., Katta, S. S., Bhat, D., & Upadya, S. P. (2022). Customized Deep Learning Classifier for Detection of Acute Lymphoblastic Leukemia Using Blood Smear Images. Healthcare, 10(10), 1812.
[10] Shafique, S., & Tehsin, S. (2018). Acute lymphoblastic leukaemia detection and classification of its subtypes using pretrained deep convolutional neural networks. Technology in Cancer Research & Treatment, 17.
[11] Singhal, V., & Singh, P. (2014). Local binary pattern for automatic detection of acute lymphoblastic leukaemia. In Proceedings of the 20th National Conference on Communications (pp. 1-5).



10.22214/IJRASET

45.98

IMPACT FACTOR: 7.129

IMPACT FACTOR: 7.429

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY